Identification
Name Pegaptanib
Accession Number DB04895
Type biotech
Description Pegaptanib is a pegylated anti-VEGF aptamer, a single strand of nucleic acid that binds with specificity to a particular target. Pegaptanib specifically binds to VEGF 165, a protein that plays a critical role in angiogenesis (the formation of new blood vessels) and increased permeability (leakage from blood vessels), two of the primary pathological processes responsible for the vision loss associated with neovascular AMD. [Wikipedia]
Structure
Categories (*)
Molecular Weight 50000.0000
Groups approved
Monoisotopic Weight Not Available
Pharmacology
Indication For the treatment of neovascular (wet) age-related macular degeneration.
Mechanism of action Pegaptanib binds to the major pathological VEGF isoform, extracellular VEGF165, thereby inhibiting VEGF165 binding to its VEGF receptors. The inhibition of VEGF164, the rodent counterpart of human VEGF165, was effective at suppressing pathological neovascularization.
Absorption In animals, pegaptanib is slowly absorbed into the systemic circulation from the eye after intravitreous administration.
Protein binding Not Available
Biotransformation Based on preclinical data, pegaptanib is metabolized by endo- and exonucleases.
Route of elimination Not Available
Toxicity Not Available
Affected organisms
  • Humans and other mammals
Interactions
Drug Interactions Not Available
Food Interactions Not Available
Neuropilin-1
Name Neuropilin-1
Gene Name NRP1
Pharmacological action unknown
Actions Not Available
References
  • Vinores SA: Pegaptanib in the treatment of wet, age-related macular degeneration. Int J Nanomedicine. 2006;1(3):263-8. - Pubmed
DTHybrid score 1.1667